Arbuckle Stuart A
SEC CIK 1557290 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | Dir | 11.7K | — | — | 3 | 2024-06-21 | 2026-06-23 |
| PRAX | Praxis Precision Medicines, Inc. | Dir | 2,537 | — | — | 2 | 2026-02-06 | 2026-06-10 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | Dir | 671 | — | — | 1 | 2026-05-20 | 2026-05-20 |
| VRTX | Vertex Pharmaceuticals | EVP, COO | 63.4K | — | $28.83M | 45 | 2021-11-15 | 2025-07-01 |
Most active insiders at RYTM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lee Jennifer Kayden | EVP, Head of North America | — | $8.90M |
| 2 | Smith Hunter C | CFO | — | $8.84M |
| 3 | Mazabraud Yann | EVP, Head of International | — | $6.62M |
| 4 | Meeker David P | Pres, CEO, Dir | — | $5.13M |
| 5 | TETRAULT LYNN A. | Dir | — | $3.71M |
| 6 | Shulman Joseph | Chief Technical Off | — | $3.67M |
| 7 | Cramer Pamela J. | CHRO | — | $2.99M |
| 8 | German Christopher Paul | CAO, Corp. Ctrl | — | $930.9K |
| 9 | Garfield Alastair | CSO | — | $912.7K |
| 10 | Arbuckle Stuart A | Dir | — | — |
Transactions 51
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-25 18:03 | 2026-06-23 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Arbuckle Stuart A | Dir | M - OptEx | — | +4,712 | 11.7K | +67% | — |
| D | 2026-06-12 17:24 | 2026-06-10 | PRAX | Praxis Precision Medicines, Inc. | Arbuckle Stuart A | Dir | A - Grant | $0.00 | +1,371 | 2,537 | +118% | $0 |
| D | 2026-05-22 16:04 | 2026-05-20 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Arbuckle Stuart A | Dir | A - Grant | $0.00 | +671 | 671 | New | $0 |
| DM | 2026-02-10 | 2026-02-06 | PRAX | Praxis Precision Medicines, Inc. | Arbuckle Stuart A | Dir | A - Grant | $0.00 | +1,166 | 1,166 | New | $0 |
| 2025-07-02 | 2025-07-01 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $450.23 | -37.2K | 63.4K | -37% | -$16.77M | |
| D | 2025-06-23 | 2025-06-18 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Arbuckle Stuart A | Dir | M - OptEx | — | +4,000 | 7,000 | +133% | — |
| 2025-05-15 | 2025-05-13 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +37.6K | 100.6K | +60% | $0 | |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $479.61 | -7,071 | 62.9K | -10% | -$3.39M | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $483.28 | -4,716 | 70.0K | -6% | -$2.28M | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $463.46 | -2,724 | 74.7K | -4% | -$1.26M | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +7,903 | 77.4K | +11% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $467.98 | -3,220 | 69.5K | -4% | -$1.51M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +23.1K | 64.3K | +56% | $0 |
| D | 2024-06-25 | 2024-06-21 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Arbuckle Stuart A | Dir | M - OptEx | — | +3,000 | 3,000 | New | — |
| 2024-05-17 | 2024-05-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $430.93 | -69 | 49.7K | -0.1% | -$29.7K | |
| 2024-02-27 | 2024-02-26 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $425.70 | -5,034 | 49.7K | -9% | -$2.14M | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $431.79 | -4,714 | 54.7K | -8% | -$2.04M | |
| 2024-02-23 | 2024-02-21 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $421.77 | -3,603 | 59.4K | -6% | -$1.52M | |
| 2024-02-21 | 2024-02-20 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $420.79 | -4,804 | 63.0K | -7% | -$2.02M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $422.54 | -7,872 | 67.8K | -10% | -$3.33M |
| 2024-02-13 | 2024-02-12 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $420.24 | -4,295 | 75.7K | -5% | -$1.80M | |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $422.74 | -3,177 | 80.0K | -4% | -$1.34M | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +26.6K | 74.7K | +55% | $0 |
| D | 2023-12-15 | 2023-12-13 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | M - OptEx | $187.53 | +8,603 | 65.2K | +15% | +$1.61M |
| D | 2023-12-15 | 2023-12-13 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $399.00 | -8,603 | 56.6K | -13% | -$3.43M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | M - OptEx | $187.53 | +8,603 | 65.2K | +15% | +$1.61M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $349.00 | -8,603 | 56.6K | -13% | -$3.00M |
| 2023-06-01 | 2023-05-30 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $329.82 | -82 | 56.6K | -0.1% | -$27.0K | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $287.47 | -5,034 | 57.8K | -8% | -$1.45M |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $289.12 | -4,714 | 61.6K | -7% | -$1.36M | |
| M | 2023-02-24 | 2023-02-22 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $294.33 | -2,401 | 66.3K | -3% | -$706.7K |
| M | 2023-02-22 | 2023-02-21 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $293.75 | -2,402 | 68.7K | -3% | -$705.6K |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $292.85 | -4,498 | 71.1K | -6% | -$1.32M | |
| M | 2023-02-16 | 2023-02-14 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $298.68 | -6,398 | 79.7K | -7% | -$1.91M |
| M | 2023-02-14 | 2023-02-13 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $298.92 | -4,887 | 82.0K | -6% | -$1.46M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $296.84 | -9,362 | 86.9K | -10% | -$2.78M |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +38.2K | 96.3K | +66% | $0 |
| 2022-12-08 | 2022-12-06 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +12.8K | 58.0K | +28% | $0 | |
| DM | 2022-08-17 | 2022-08-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $303.93 | -22.2K | 61.6K | -26% | -$6.74M |
| D | 2022-08-17 | 2022-08-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +6,571 | 67.5K | +11% | +$1.02M |
| DM | 2022-08-12 | 2022-08-10 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.40 | -180 | 60.9K | -0.3% | -$54.1K |
| D | 2022-08-12 | 2022-08-10 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +64 | 61.1K | +0.1% | +$9,956 |
| DM | 2022-08-10 | 2022-08-09 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.67 | -5,690 | 61.9K | -8% | -$1.71M |
| D | 2022-08-10 | 2022-08-09 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +1,926 | 66.7K | +3% | +$299.6K |
| M | 2022-05-18 | 2022-05-16 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $251.19 | -133 | 64.9K | -0.2% | -$33.4K |
| 2022-05-04 | 2022-05-02 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $263.98 | -306 | 64.8K | -0.5% | -$80.8K | |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $227.86 | -7,246 | 65.1K | -10% | -$1.65M | |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $232.51 | -4,126 | 72.3K | -5% | -$959.3K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | F - Tax | $237.74 | -3,040 | 76.4K | -4% | -$722.7K | |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +38.4K | 79.5K | +93% | $0 |
| M | 2021-11-16 | 2021-11-15 | VRTX | Vertex Pharmaceuticals | Arbuckle Stuart A | EVP, COO | S - Sale | $187.26 | -3 | 41.1K | -0.0% | -$561.78 |
Purchase Sale Sale after option exercise All abbreviations